Compare CRS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRS | MRNA |
|---|---|---|
| Founded | 1910 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3B | 21.6B |
| IPO Year | 1994 | 2018 |
| Metric | CRS | MRNA |
|---|---|---|
| Price | $559.49 | $49.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | ★ $419.75 | $34.27 |
| AVG Volume (30 Days) | 562.9K | ★ 5.1M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 100.54 | 21.77 |
| EPS | ★ 7.29 | N/A |
| Revenue | $2,157,700,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $9.21 | $9.36 |
| Revenue Next Year | $10.50 | $15.43 |
| P/E Ratio | $71.75 | ★ N/A |
| Revenue Growth | ★ 20.03 | 4.29 |
| 52 Week Low | $228.00 | $22.28 |
| 52 Week High | $537.41 | $59.55 |
| Indicator | CRS | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 80.49 | 53.49 |
| Support Level | $297.11 | $45.09 |
| Resistance Level | N/A | $54.50 |
| Average True Range (ATR) | 19.36 | 2.83 |
| MACD | 8.35 | 0.19 |
| Stochastic Oscillator | 99.61 | 74.13 |
Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.